Analysis
Thyme Care closed more than $125 million in a Series E led by Morgan Health, JPMorgan's health investment arm, at a valuation above $2 billion, CNBC reported. Humana and CVS Health Ventures joined, along with AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures and a16z Bio + Health.
The Nashville-based company runs oncology navigation: nurses, social workers and care coordinators who stay with a cancer patient between appointments, catch symptoms before they turn into emergency admissions, and steer treatment toward in-network, evidence-based options. It contracts with payers and risk-bearing providers rather than billing patients, which is why Humana and CVS appear as both investors and the archetypal customer.
Scale moved fast. Thyme Care was managing roughly 10,000 patients at the end of 2024 and 135,000 actively treated cancer patients as of August 2026, with services available to more than 10.5 million covered lives across all 50 states. It says it now touches more than $7 billion in oncology spend -- the number that matters, because value-based oncology contracts pay on total cost of care against a benchmark.
“Thyme Care was founded in 2020 by Robin Shah, previously of Flatiron Health, and Bobby Green, an oncologist who also came out of Flatiron.”
The raise also establishes a parent entity, Thyme Companies, to house adjacent businesses starting with biosimilar adoption and clinical trial accrual. Both are real margin pools: biosimilars can cut drug spend materially per patient, and trial enrollment is a service pharma pays for directly.
A Mixed Record on Exits
The comparison set is not encouraging on exits. Value-based specialty care has produced strong private marks and weak public ones -- Agilon Health and Privia have traded well below their IPO enthusiasm, and Oncology Care Partners and Jasper Health struggled to scale contracts. Thyme Care's answer is that navigation is asset-light relative to owning clinics, and that payers now have hard data on avoided admissions. That claim is testable, and the audited savings per patient is the figure any Series E investor should have seen.
Thyme Care was founded in 2020 by Robin Shah, previously of Flatiron Health, and Bobby Green, an oncologist who also came out of Flatiron. That lineage matters: Flatiron built the oncology data infrastructure that Roche bought for $1.9 billion in 2018, and the founding team's thesis is that the same visibility into treatment patterns is worth more when it is attached to care delivery rather than sold as data.
Why Oncology Is the Right Beachhead
Oncology is the right beachhead for a value-based model because the spend is concentrated and the waste is legible. Cancer care runs 10 to 15 percent of total medical spend for most commercial plans, emergency admissions during chemotherapy are common and largely preventable, and end-of-life care is where cost and patient experience diverge most sharply. A navigation layer that reduces avoidable admissions produces savings a payer actuary can measure within a year.
The competitive field includes Carrum Health and Included Health on the benefits side, Jasper and Reimagine Care in oncology specifically, and the payers' own in-house navigation teams -- which are the real competitor, since every plan already has case managers and must be convinced an outside vendor does it better.
At roughly $2 billion, the company is priced for a payer acquisition, and its two strategic investors are the most obvious buyers. That is a comfortable position and a constrained one: strategics on the cap table tend to narrow the field of bidders rather than widen it.
